Psychedelic trials face a difficult challenge: a distinctive drug experience can reveal treatment assignment and influence expectations. That can complicate the interpretation of clinical outcomes, even when independent assessors remain blinded. Better masking could help clarify how much benefit is attributable to the treatment being tested.
The field has been managing around that problem rather than solving it. A Viewpoint published in JAMA Psychiatry proposes a more structural answer: UMBRAA, or unidentifiable multidrug blinding with reduced, authorized awareness. Rather than assuming participants cannot tell what they took, it tries to make the specific assignment hard to infer in the first place.
UMBRAA combines multidrug active placebos with authorized incomplete disclosure, where participants agree beforehand that certain study details will be withheld, to make treatment assignment harder to infer. It remains an untested proposal: the safety of the combinations, their own therapeutic effects, their ability to preserve masking, and the consent safeguards all require evaluation.
Why Standard Active Placebos Fall Short
The usual answer has been an active placebo that produces physiological noise: warmth, flushing, mild dizziness. Usona Institute’s Phase 2 trial took that route, comparing 25 mg psilocybin against 100 mg niacin in 104 participants across 11 US sites, published in JAMA in 2023. The design is reasonable, and it imports a ceiling. Niacin’s effects are brief; psilocybin’s subjective effects run for hours, so a participant with a half day of introspective experience is unlikely to be uncertain about what they received.
That trial handled the assessor side carefully. MADRS ratings were collected by remote central telephone raters rather than by clinicians who had watched participants come out of a medicine session, which closes one channel of unblinding. It does not close the participant’s own. The authors acknowledged that functional unblinding was likely, and the trial did not measure how well masking actually held.
The MAPS MDMA-assisted therapy program for PTSD ran two Phase 3 trials, MAPP1 and MAPP2, using blinded independent raters. The subjective signature of MDMA is distinct enough that participants and therapists could often form strong guesses about assignment, and participant and therapist unblinding can still move self-reported outcomes even when the rater is blinded. When FDA’s advisory committee reviewed the submission, expectation bias sat near the center of the critique. Without data on how well masking held, every effect size in the dataset is harder to interpret.
What makes UMBRAA different in principle is that it does not ask participants to be unaware of their own experience. It asks them to be unaware of their specific assignment within a set of active conditions. If you might have received psilocybin, a low dose psychedelic, or a dissociative comparator, the experience alone does not decode the envelope. Whether that holds in practice is exactly what has not been tested.
Two questions are easy to collapse into one and worth keeping apart. The first is whether the subjective experience itself contributes to the therapeutic benefit, which remains open and plausible. The second is whether knowing your assignment biases what you report. Better masking is aimed at the second, and pursuing it does not require assuming the answer to the first.
What This Means for How Trials Get Built
FDA’s July 2026 guidance recommends central blinded raters and consideration of blinding and expectancy questionnaires. It encourages innovative control strategies but does not mandate masking-verification endpoints or endorse UMBRAA. The guidance is nonbinding, and psychedelic drugs remain subject to the same approval standards as other drugs.
For sponsors, the practical reading is narrower than the conversation around the guidance suggests. Nothing requires a masking-verification endpoint. What has changed is that the agency has now named the questions it expects to see addressed, and a program that can show who rated the outcomes, how well masking held, and what unblinding appeared to do to the estimate is in a better position at review than one that offers masking success as an assumption. Trade coverage of the final guidance has read it the same way.
In my role overseeing clinical care at Mindbloom, where more than 800,000 ketamine treatment sessions have been facilitated, the clinical parallel is familiar. People arrive with an expectation about what they are going to feel, and those expectations interact with how they later describe their symptoms in ways standard rating scales were not built to separate. A masking framework like UMBRAA would force trial designers to address that interaction directly rather than assume randomization absorbs it.
What Better Masking Would Actually Buy
The familiar worry is that stronger blinding will shrink the effect sizes the field has reported. That is worth taking seriously, and it is also not the point. The value of better masking is greater confidence in what the results mean, whatever the size of the effect. The next step is to test whether these approaches improve interpretability without adding unacceptable risks or new confounding effects.
What I am watching next is whether sponsors running Phase 3 psilocybin and MDMA programs start reporting masking success as a measured variable rather than describing the control arm and moving on. That will show up in protocol amendments and statistical analysis plans before it shows up in any readout, and it is a reasonable thing to ask for while proposals like UMBRAA are still being evaluated. For background on what the agency actually asked for, see our earlier read of the July 2026 guidance.
References
- JAMA Psychiatry Viewpoint proposing UMBRAA (unidentifiable multidrug blinding with reduced, authorized awareness)
- Federal Register, “Psychedelic Drugs: Considerations for Clinical Investigations,” FDA guidance finalized July 14, 2026 (nonbinding)
- Applied Clinical Trials, FDA finalizes guidance on psychedelic drug development
- Raison CL, et al. Single-dose psilocybin for major depressive disorder. JAMA. 2023;330(9):843-853. Usona Institute PSIL201, 104 participants, 11 US sites, 25 mg psilocybin vs 100 mg niacin, MADRS by remote central raters
- MAPS Phase 3 MDMA-assisted therapy program for PTSD (MAPP1 and MAPP2)
Dr. Leonardo Vando, MD is Principal Investigator of Psychiatry at Vando Medical Services.
